Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study

BACKGROUND: COVID-19 is associated with both venous and arterial thrombotic complications. While prophylactic anticoagulation is now widely recommended for hospitalized patients with COVID-19, the effectiveness and safety of thromboprophylaxis in outpatients with COVID-19 has not been established. S...

Descripción completa

Detalles Bibliográficos
Autores principales: Capell, Warren H., Barnathan, Elliot S., Piazza, Gregory, Spyropoulos, Alex C., Hsia, Judith, Bull, Scott, Lipardi, Concetta, Sugarmann, Chiara, Suh, Eunyoung, Rao, Jaya Prakash, Hiatt, William R., Bonaca, Marc P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871775/
https://www.ncbi.nlm.nih.gov/pubmed/33577800
http://dx.doi.org/10.1016/j.ahj.2021.02.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871775/
https://www.ncbi.nlm.nih.gov/pubmed/33577800
http://dx.doi.org/10.1016/j.ahj.2021.02.001

Ejemplares similares